Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
A suggested positive control is mouse kidney tissue lysate.
PA5-20821 can be used with blocking peptide PEP-0935.
RWDD3 (RSUME), a small RWD-containing protein, has a central role in sumoylation by enhancing SUMO conjugation in the regulatory network of immune-inflammatory signals. RWDD3 increases Ikappa-Beta sumoylation and stability. In addition, RWDD3 inhibits TNF-a-induced kappaB-LUC (Luciferase) reporter activity, showing the functional consequence of Ikappa-Beta increased stability. RSUME-enhanced sumoylation of Ikappa-Beta leads to the inhibition of NF-kappa-Beta activity on two well-known inflammatory genes, IL-8 and cyclooxygenase-2 (Cox-2) and therefore may also favor anti-inflammatory pathways. Expression of RWDD3 was induced under hypoxic conditions and it has a potential role during vascularization. Both BMP-4 and RWDD3 may be interesting targets for inhibiting steps involved in pituitary tumorigenesis.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
蛋白别名: pituitary tumor X2CR1 protein; RSUME; RWD domain-containing protein 3; RWD domain-containing sumoylation enhancer; RWD-containing sumoylation enhancer
基因别名: 2510027J23Rik; 3110037C01Rik; AI035684; AI662458; Rsume; Rwdd3; X2CR1
UniProt ID: (Rat) P0C7N0
Entrez Gene ID: (Rat) 65026, (Mouse) 66568